{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T20:51:10Z","timestamp":1724359870602},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T00:00:00Z","timestamp":1388793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10689-013-9697-9","type":"journal-article","created":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T07:51:41Z","timestamp":1388735501000},"page":"197-203","source":"Crossref","is-referenced-by-count":4,"title":["Baseline and post prophylactic tubal\u2013ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers"],"prefix":"10.1007","volume":"13","author":[{"name":"The Carrier Clinic Collaborators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Bancroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Arden-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Saya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Wakeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalind","family":"Eeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,4]]},"reference":[{"issue":"4","key":"9697_CR1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","volume":"3","author":"IJ Jacobs","year":"2004","unstructured":"Jacobs IJ, Menon U (2004) Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3(4):355\u2013366","journal-title":"Mol Cell Proteomics"},{"issue":"21","key":"9697_CR2","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654\u20132663","journal-title":"J Clin Oncol"},{"issue":"2","key":"9697_CR3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","volume":"121","author":"S Zhang","year":"2011","unstructured":"Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA (2011) Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121(2):353\u2013357","journal-title":"Gynecol Oncol"},{"issue":"5645","key":"9697_CR4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"M-C King","year":"2003","unstructured":"King M-C, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643\u2013646","journal-title":"Science"},{"issue":"5","key":"9697_CR5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah P, Narod S, Risch HA, Eyfjord JE, Hopper J, Loman N, Olsson H, Johannsson O, Borg \u00c5 (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Human Genet 72(5):1117\u20131130","journal-title":"Am J Human Genet"},{"issue":"9","key":"9697_CR6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jmg.2008.058248","volume":"46","author":"DG Evans","year":"2009","unstructured":"Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, D\u00f8rum A, Steel M, Lalloo F, Apold J, Porteous M (2009) Screening for familial ovarian cancer: poor survival of BRCA1\/2 related cancers. J Med Genet 46(9):593\u2013597","journal-title":"J Med Genet"},{"issue":"6","key":"9697_CR7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/sj.bjc.6603015","volume":"94","author":"A Oei","year":"2006","unstructured":"Oei A, Massuger L, Bulten J, Ligtenberg M, Hoogerbrugge N, De Hullu J (2006) Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 94(6):814\u2013819","journal-title":"Br J Cancer"},{"issue":"1","key":"9697_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2011.39.7638","volume":"31","author":"AN Rosenthal","year":"2013","unstructured":"Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ (2013) Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol Off J Am Soc Clin Oncol 31(1):49\u201357","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"9697_CR9","doi-asserted-by":"crossref","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc 304(9):967\u2013975","DOI":"10.1001\/jama.2010.1237"},{"issue":"43","key":"9697_CR10","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1038\/sj.onc.1209881","volume":"25","author":"SM Domchek","year":"2006","unstructured":"Domchek SM, Weber B (2006) Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25(43):5825\u20135831","journal-title":"Oncogene"},{"issue":"5","key":"9697_CR11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","volume":"68","author":"RC Bast Jr","year":"1981","unstructured":"Bast RC Jr, Feeney M, Lazarus H, Nadler L, Colvin R, Knapp R (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Investig 68(5):1331","journal-title":"J Clin Investig"},{"issue":"1","key":"9697_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/GCO.0b013e3282f2b124","volume":"20","author":"E H\u00f8gdall","year":"2008","unstructured":"H\u00f8gdall E (2008) Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol 20(1):4\u20138","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"2","key":"9697_CR13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijgo.2007.06.003","volume":"99","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi H, Ooi H, Yamada Y, Sakata M, Kawaguchi R, Kanayama S, Sumimoto K, Terao T (2007) Serum CA125 level before the development of ovarian cancer. Int J Gynecol Obstet 99(2):95\u201399","journal-title":"Int J Gynecol Obstet"},{"issue":"15","key":"9697_CR14","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","volume":"309","author":"RC Bast Jr","year":"1983","unstructured":"Bast RC Jr, Klug TL, John ES, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 309(15):883\u2013887","journal-title":"New Engl J Med"},{"issue":"2","key":"9697_CR15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0020-7292(90)90588-C","volume":"33","author":"S Granberg","year":"1990","unstructured":"Granberg S, Wikland M, Friberg L-G (1990) Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause. Int J Gynecol Obstet 33(2):149\u2013152","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"9697_CR16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0090-8258(90)90130-D","volume":"36","author":"VR Zurawski","year":"1990","unstructured":"Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, Eklund G, Mattsson B, Connor RJ, Prorok PC (1990) Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol 36(3):299\u2013305","journal-title":"Gynecol Oncol"},{"issue":"2","key":"9697_CR17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/gme.0b013e3181ecfb51","volume":"18","author":"AM Altena van","year":"2011","unstructured":"van Altena AM, Holtsema H, Hendriks JC, Massuger LF, de Hullu JA (2011) Cancer antigen 125 level after a bilateral salpingo-oophorectomy: what is the contribution of the ovary to the cancer antigen 125 level? Menopause 18(2):133\u2013137","journal-title":"Menopause"},{"key":"9697_CR18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","volume":"70","author":"J Benedet","year":"2000","unstructured":"Benedet J, Bender H, Jones H III, Ngan H, Pecorelli S (2000) FIGO Committee on gynecologic oncology. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70:209\u2013262","journal-title":"Int J Gynecol Obstet"},{"issue":"3","key":"9697_CR19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004347-198303000-00005","volume":"2","author":"S Kabawat","year":"1983","unstructured":"Kabawat S, Bast R Jr, Bhan A, Welch WR, Knapp R, Colvin R (1983) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2(3):275\u2013285","journal-title":"Int J Gynecol Pathol"},{"issue":"11","key":"9697_CR20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00006254-199411000-00018","volume":"49","author":"T Alagoz","year":"1994","unstructured":"Alagoz T, Buller RE, Berman M, Anderson B, Manetta A, DiSaia P (1994) What is a normal CA 125 level? Obstet Gynecol Surv 49(11):764\u2013765","journal-title":"Obstet Gynecol Surv"},{"issue":"2","key":"9697_CR21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0090-8258(03)00051-9","volume":"89","author":"JL Wilder","year":"2003","unstructured":"Wilder JL, Pavlik E, Straughn JM, Kirby T, Higgins RV, DePriest PD, Ueland FR, Kryscio RJ, Whitley RJ, Nagell JV (2003) Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 89(2):233\u2013235","journal-title":"Gynecol Oncol"},{"issue":"3","key":"9697_CR22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ygyno.2006.06.032","volume":"103","author":"K Bosse","year":"2006","unstructured":"Bosse K, Rhiem K, Wappenschmidt B, Hellmich M, Madeja M, Ortmann M, Mallmann P, Schmutzler R (2006) Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 103(3):1077\u20131082","journal-title":"Gynecol Oncol"},{"issue":"3","key":"9697_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/gyno.1998.5018","volume":"69","author":"T Kurihara","year":"1998","unstructured":"Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T (1998) Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol 69(3):192\u2013196","journal-title":"Gynecol Oncol"},{"issue":"4","key":"9697_CR24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ejca.2004.10.029","volume":"41","author":"H Vasen","year":"2005","unstructured":"Vasen H, Tesfay E, Boonstra H, Mourits M, Rutgers E, Verheyen R, Oosterwijk J, Beex L (2005) Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 41(4):549\u2013554","journal-title":"Eur J Cancer"},{"issue":"11","key":"9697_CR25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jnci\/90.11.797","volume":"90","author":"A Eisen","year":"1998","unstructured":"Eisen A, Weber BL (1998) Primary peritoneal carcinoma can have multifocal origins: implications for prophylactic oophorectomy. J Natl Cancer Inst 90(11):797\u2013798","journal-title":"J Natl Cancer Inst"},{"issue":"8302","key":"9697_CR26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(82)92681-2","volume":"320","author":"J Tobacman","year":"1982","unstructured":"Tobacman J, Tucker M, Kase R, Greene M, Costa J, Fraumeni JRJ (1982) Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet 320(8302):795\u2013797","journal-title":"Lancet"},{"issue":"9","key":"9697_CR27","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1002\/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J","volume":"71","author":"MS Piver","year":"1993","unstructured":"Piver MS, Jishi MF, Tsukada Y, Nava G (1993) Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71(9):2751\u20132755","journal-title":"Cancer"},{"issue":"18","key":"9697_CR28","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358\u20131365","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"9697_CR29","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2003.04.131","volume":"21","author":"DA Levine","year":"2003","unstructured":"Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21(22):4222\u20134227","journal-title":"J Clin Oncol"},{"issue":"8","key":"9697_CR30","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/sj.bjc.6601692","volume":"90","author":"R Olivier","year":"2004","unstructured":"Olivier R, Van Beurden M, Lubsen M, Rookus M, Mooij T, Van de Vijver M, Van\u2019t Veer L (2004) Clinical outcome of prophylactic oophorectomy in BRCA1\/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90(8):1492\u20131497","journal-title":"Br J Cancer"},{"key":"9697_CR31","doi-asserted-by":"crossref","unstructured":"Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade O, McLennan J, Karlan B, Weitzel J, Sun P, Narod S (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc 296(2):185\u2013192","DOI":"10.1001\/jama.296.2.185"},{"issue":"10","key":"9697_CR32","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ejso.2006.03.021","volume":"32","author":"W Gotlieb","year":"2006","unstructured":"Gotlieb W, Barchana M, Ben-Baruch G, Friedman E (2006) Malignancies following bilateral salpingo-oophorectomy (BSO). Eur J Surg Oncol 32(10):1231\u20131234","journal-title":"Eur J Surg Oncol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-013-9697-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10689-013-9697-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-013-9697-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T08:16:31Z","timestamp":1647850591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10689-013-9697-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9697"],"URL":"https:\/\/doi.org\/10.1007\/s10689-013-9697-9","relation":{},"ISSN":["1389-9600","1573-7292"],"issn-type":[{"type":"print","value":"1389-9600"},{"type":"electronic","value":"1573-7292"}],"subject":[],"published":{"date-parts":[[2014,1,4]]}}}